The research and development projects implemented by the Company, in accordance with the decision of the Management Board of April 3, 2019 are classified into the following three groups:
A group of projects of the greatest importance for the Company, as part of which the Company carries out work and invests funds. This group includes projects currently under way: MabionCD20, MabionMS and MabionEGFR.
New projects planned for 2019
Projects in which the Company plans to start research and development work in the second half of 2019. These will be projects concerning three biosimilar medicines in the area of autoimmunology, metabolic diseases, and oncology.
Projects in which the Company considers starting implementation in the medium or long term, preferably in cooperation with a partner. These will be projects concerning, inter alia, autoimmune and oncological diseases.